Rapid nongenomic estrogen signaling controls alcohol drinking behavior.


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
05 Nov 2023
Historique:
pubmed: 14 11 2023
medline: 14 11 2023
entrez: 14 11 2023
Statut: epublish

Résumé

The overconsumption of alcohol contributes to a multitude of negative health outcomes, especially in women, who are more susceptible to its effects and more likely to develop alcohol dependence than men with the same early history of alcohol consumption. Binge alcohol drinking is prominent during reproductive years and correlated with high circulating estrogen in women, and rodent studies show that female rodents with intact ovaries consume more alcohol than males. However, the causal role of ovarian E2 in intact animals in alcohol drinking has not been established. Here, we show that intact female mice consume more alcohol and display reduced avoidance behavior when they have elevated levels of circulating E2 during proestrus compared to other estrous cycle stages in individual mice. We found that high ovarian E2 promotes alcohol drinking in females, but not anxiolysis, through rapid nongenomic E2 signaling at ERα in the bed nucleus of the stria terminalis (BNST). Acute administration of intra-BNST E2 in low ovarian E2 mice enhanced binge alcohol intake, while acute systemic inhibition of E2 synthesis and acute blockade of ERα signaling in the BNST reversed the pro-drinking effects of high ovarian E2 status. In contrast, acute E2 manipulations were unable to alter the effects of ovarian E2 status on avoidance behavior, suggesting genomic mechanisms are required for the anxiolytic effects of ovarian E2. We further show that corticotropin-releasing factor (CRF) neurons in the BNST are an important mediator of these effects of rapid E2 signaling, as high E2 rapidly enhanced synaptic excitation of BNST

Identifiants

pubmed: 37961707
doi: 10.1101/2023.11.02.565358
pmc: PMC10635092
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIH HHS
ID : P51 OD011092
Pays : United States

Auteurs

L J Zallar (LJ)

Pharmacology Graduate Program, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.

J K Rivera-Irizarry (JK)

Neuroscience Graduate Program, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.

P U Hamor (PU)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

I Pigulevskiy (I)

Pharmacology Graduate Program, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.

D Liu (D)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

J P Welday (JP)

Neuroscience Graduate Program, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.

A S Rico Rozo (AS)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

R Bender (R)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

J Asfouri (J)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

O B Levine (OB)

Neuroscience Graduate Program, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.

M J Skelly (MJ)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

C K Hadley (CK)

Weill Cornell/Rockefeller/Sloan Kettering Tri-institutional MD-PhD Program, New York, NY 10065, USA.

K M Fecteau (KM)

Endocrine Technologies Core, Oregon National Primate Research Center, Beaverton, OR, USA.

H Mehanna (H)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

S Nelson (S)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

J Miller (J)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

P Ghazal (P)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

P Bellotti (P)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

D W Erikson (DW)

Endocrine Technologies Core, Oregon National Primate Research Center, Beaverton, OR, USA.

J Geri (J)

Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

K E Pleil (KE)

Pharmacology Graduate Program, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Neuroscience Graduate Program, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

Classifications MeSH